Due Diligence Capital Notes

Seven weeks. That's how long it took Core Scientific's new bridge loans to get replaced. On March 4, 2026, the company signed a delayed-draw bridge credit agreement — essentially a short-term borrowing facility designed to cover immediate capital needs while permanent financing is arranged. By April 21, 2026, management had already filed an 8-K announcing plans to raise $3.3 billion in senior secured notes to retire that bridge debt. The speed of that cycle is striking. It suggests a company moving under genuine urgency, making large-scale financing decisions in compressed timeframes.

But the most important detail in this announcement isn't the size of the offering or even its purpose. It's who is actually issuing the debt. The $3.3 billion in notes are not being issued by Core Scientific, Inc. — the public company trading under the ticker CORZ. They're being issued by an entity called Core Scientific Finance I LLC, described in the filing as an "indirect subsidiary" of the parent. And the parent company has stated explicitly, in its own 8-K, that it is "not guaranteeing the Notes proposed to be issued by the Issuer in the Offering." That one sentence rewrites the entire structural map for anyone trying to evaluate what this refinancing really means.

The Architecture of a Subsidiary Debt Offering

When a public company wants to raise debt capital, it has choices. It can borrow directly at the parent level — where the creditworthiness of the whole enterprise backs the loan — or it can create a subsidiary entity to be the formal borrower, secured against specific assets within the corporate structure. Core Scientific has chosen the latter path, and understanding why that matters requires a brief primer on two concepts: senior secured notes and structural subordination.

Senior secured notes are bonds where the lender holds a legal claim against specific collateral — in this case, the operating assets of five named data-center subsidiaries — and where that claim ranks ahead of unsecured lenders in any bankruptcy or liquidation scenario. "Senior" means first in line; "secured" means the claim is tied to real assets, not just a promise to pay.

Structural subordination is the flip side of that coin. When debt sits at a subsidiary level and the parent company is not a guarantor, the parent's own creditors — and by extension, its equity shareholders — sit below the subsidiary's creditors in the recovery hierarchy. The subsidiary note holders get paid first from those five operating locations. Whatever is left, if anything, flows up to the parent. Equity is last in line, as it always is. But subsidiary structures create an extra layer of distance between equity investors and the underlying assets.

This is the framework Core Scientific has constructed for its $3.3 billion refinancing. It's a common structure in infrastructure-heavy businesses — project finance, real estate, energy — but it deserves close attention from anyone holding or considering CORZ shares.

Breaking Down the Moving Parts

Here's how the mechanics of this offering work, step by step:

The legal issuer: Core Scientific Finance I LLC. This indirect subsidiary is the formal borrower. It will receive the $3.3 billion in proceeds from institutional bond investors. The notes it issues will be senior secured obligations of this entity — not of Core Scientific, Inc.
The five operating guarantors. Five subsidiaries are pledging their assets as collateral to back the notes: Core Scientific Austin LLC, Core Scientific Denton LLC, Core Scientific Dalton LLC, Core Scientific Marble LLC, and Core Scientific Muskogee LLC. These names correspond to the company's data-center and Bitcoin-mining campuses across the United States. These facilities — the servers, the power infrastructure, the real estate — are what the note holders ultimately have a claim against.
The distribution mechanism. The finance subsidiary doesn't keep the $3.3 billion. According to the April 21, 2026 8-K filing, the issuer "intends to use a substantial portion of the net proceeds from the Offering to pay a distribution to the Company" — meaning it will send most of the money upward to the parent. The parent then uses those funds to repay its bridge loans.
The bridge loans being retired. The delayed-draw term loans originated on March 4, 2026, were amended on March 18, 2026 — just two weeks after origination. The fact that Core Scientific needed to amend a credit agreement within fourteen days of signing it suggests the initial terms were either insufficient or that the company's situation evolved rapidly. These loans are now being retired, along with "accrued interest thereon and fees and expenses."
The target audience: institutional investors only. The notes are being offered under Rule 144A, a SEC exemption that allows the sale of securities to qualified institutional buyers (QIBs) — pension funds, insurance companies, large asset managers — without the full public registration process. They're also being offered to non-U.S. investors under Regulation S, another exemption for offshore sales. No public equity is being issued. Retail investors cannot participate in the placement directly.
The maturity: 2031. The five-year runway gives Core Scientific time to grow its high-performance computing (HPC) and Bitcoin-mining revenues enough to service this debt. The next refinancing cliff, if nothing is repaid early, lands five years out.

What the Filing Actually Says

The language in Core Scientific's 8-K is careful and worth reading directly. On the distribution of proceeds, the filing states:

"The Issuer intends to use a substantial portion of the net proceeds from the Offering to pay a distribution to the Company, which the Company intends to use in part to repay in full its outstanding delayed draw term loans, including accrued interest thereon and fees and expenses in connection therewith."

That phrase "in part" is worth flagging. It implies that after retiring the bridge loans, some capital may remain for other corporate purposes — though the filing does not specify what those might be.

On the structural separation between the parent and the notes, the filing is explicit:

"The Company is not issuing any securities in connection with the Offering, nor is the Company guaranteeing the Notes proposed to be issued by the Issuer in the Offering."

This is a deliberate legal choice. Keeping the parent company off the guarantee line may offer certain structural flexibility, but it also means that if the subsidiary notes ever become impaired, the parent cannot be compelled to make them whole. For equity investors in CORZ, that's a structural buffer — but it also means that in a severe stress scenario, the path to recovering value is more convoluted.

You can review the full filing index for Core Scientific on SEC EDGAR here.

The Broader Context: Why $3.3 Billion Now?

Core Scientific emerged from Chapter 11 bankruptcy in early 2024 with a restructured balance sheet and ambitions to pivot from pure-play Bitcoin mining toward higher-margin HPC hosting — leasing its data-center infrastructure to artificial intelligence compute customers who need large amounts of reliable power and cooling. That pivot requires capital. Lots of it. Data-center builds are measured in hundreds of megawatts, and power infrastructure doesn't come cheap.

The bridge loan originated in March 2026 was presumably funding some portion of that buildout — or bridging the company through a gap between planned cash inflows and actual spend. Refinancing bridge debt with longer-dated secured notes is a rational move if you believe your cash flows will grow into the fixed obligations. Management's willingness to layer $3.3 billion in senior secured debt onto five operating subsidiaries says something about their conviction in the revenue trajectory. Whether that conviction is warranted is what equity investors need to form their own view on.

What Could Break This Thesis

The risks here are specific and worth naming clearly.

Structural subordination in a stress scenario. Because Core Scientific, Inc. is not a guarantor, equity holders are subordinate not just to the normal creditor stack but to an entire subsidiary debt structure sitting between them and the operating assets. In a bankruptcy or restructuring, this layering complicates recovery in ways that are genuinely hard to model. Investors should not assume that a senior label at the subsidiary level has no effect on equity recovery at the parent level — it very much does.
Execution risk on the placement. This is a Rule 144A private placement — the deal gets done only if institutional buyers show up at the terms Core Scientific needs. If credit markets tighten, if risk appetite among QIBs shifts, or if due diligence raises questions about the operating assets, the $3.3 billion placement could close at a smaller size or with worse terms (higher interest rate, tighter covenants). The filing carries the standard caveat that forward-looking statements "are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially."
Leverage at a cyclical business. Bitcoin mining revenues are denominated in Bitcoin, and Bitcoin is volatile. HPC hosting revenues are more stable but are tied to AI infrastructure demand, which is itself a competitive and evolving market. Loading $3.3 billion in senior secured obligations onto the subsidiaries that generate this revenue means that in a down cycle — lower Bitcoin prices, slower HPC demand growth — fixed debt service costs do not decline. Financial flexibility shrinks exactly when you need it most.
The bridge-loan velocity question. Entering a delayed-draw credit facility on March 4, amending it on March 18, and announcing a full refinancing on April 21 compresses an enormous amount of financial decision-making into roughly seven weeks. Speed isn't inherently bad, but this pace raises a fair question: how acute was the near-term liquidity pressure that required drawing on bridge financing in the first place? The 8-K doesn't answer that directly.

Where This Leaves the Investment Thesis

Core Scientific's decision to pursue a $3.3 billion secured note offering through a subsidiary structure is a significant financial event — one that will reshape the company's balance sheet, its fixed obligations, and the structural relationship between its operating assets and its public equity for the next five years.

The move reflects management's confidence that the company's data-center and Bitcoin-mining infrastructure can generate durable cash flows sufficient to service a large debt load. If that confidence proves correct, and if HPC hosting demand continues to grow alongside a constructive Bitcoin price environment, the refinancing buys time and stability. The 2031 maturity date pushes the next capital-structure conversation years down the road, giving Core Scientific room to execute.

But the structural complexity introduced here is real and should not be underestimated. The fact that the parent company is explicitly not guaranteeing the notes means that equity investors in CORZ are participating in a structure where the most valuable operating assets are ring-fenced behind $3.3 billion in senior secured claims. That's not necessarily a dealbreaker — infrastructure companies operate this way all the time — but it is a fundamentally different risk profile than buying shares in a company where the debt sits at the parent level. Understanding that difference is the baseline for any serious analysis of what CORZ is actually worth.